GE gets clearance for additional uses for stress contrast agent

By staff writers

February 14, 2022 -- GE Healthcare has secured clearance from the European Medicines Agency for additional imaging modalities for its Rapiscan stress contrast agent.

Rapiscan is already cleared for SPECT myocardial perfusion imaging in adults. The expanded clearance now covers MRI, CT, and PET.

Rapiscan helps clinicians diagnose coronary artery disease, and it does not require weight and age-based modifications or an infusion pump, GE said.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking